The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostat

Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer

(2016) C. A. Carter et al.   ANNALS OF ONCOLOGY

Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer

(2016) Ravi A. Madan et al.   BJU INTERNATIONAL

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

Intratumoral CD14+ Cells and Circulating CD14+HLA-DRlo/neg Monocytes Correlate with Decreased Survival in Patients with Clear Cell Renal Cell Carcinoma

(2015) M. P. Gustafson et al.   CLINICAL CANCER RESEARCH

Emerging immunotherapies for bladder cancer

(2015) Joseph W. Kim et al.   CURRENT OPINION IN ONCOLOGY

Immunotherapies for bladder cancer

(2015) Farhad Fakhrejahani et al.   CURRENT OPINION IN UROLOGY

Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial

(2015) Anish Thomas et al.   LANCET ONCOLOGY

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

Immune independent crosstalk between lymphoma and myeloid suppressor CD14+HLA-DRlow/negmonocytes mediates chemotherapy resistance

(2015) Zhe (Jenny) Zhang et al.   OncoImmunology

Myeloid derived suppressor cells—An overview of combat strategies to increase immunotherapy efficacy

(2015) Oana Draghiciu et al.   OncoImmunology

HDAC inhibitors and immunotherapy; a double edged sword?

(2015) Michiel Kroesen et al.   Oncotarget

Myeloid-derived suppressor cell heterogeneity in human cancers

(2014) Samantha Solito et al.   Annals of the New York Academy of Sciences

A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study

(2014) A. Thomas et al.   CLINICAL CANCER RESEARCH

Complexity and challenges in defining myeloid-derived suppressor cells

(2014) Vera Damuzzo et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial

(2014) Arun Rajan et al.   LANCET ONCOLOGY

Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells

(2014) K. Kim et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cancer Vaccines in the World of Immune Suppressive Monocytes (CD14+HLA-DRlo/neg Cells): The Gateway to Improved Responses

(2014) Rebecca R. Laborde et al.   Frontiers in Immunology

An Intact Immune System Is Required for the Anticancer Activities of Histone Deacetylase Inhibitors

(2013) A. C. West et al.   CANCER RESEARCH

Trichostatin A Promotes the Generation and Suppressive Functions of Regulatory T Cells

(2013) Cristian Doñas et al.   Clinical & Developmental Immunology

Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor

(2013) Denise A. Yardley et al.   JOURNAL OF CLINICAL ONCOLOGY

The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity

(2013) David M. Woods et al.   MELANOMA RESEARCH

HDAC Inhibition Suppresses Primary Immune Responses, Enhances Secondary Immune Responses, and Abrogates Autoimmunity During Tumor Immunotherapy

(2013) Byram W Bridle et al.   MOLECULAR THERAPY

Regulation of HLA-DR peptide occupancy by histone deacetylase inhibitors

(2013) Kevin Cronin et al.   Human Vaccines & Immunotherapeutics

Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role

(2012) J. Huang et al.   BLOOD

Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology

(2012) Claudia A. Dumitru et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

On the armament and appearances of human myeloid-derived suppressor cells

(2012) Isabel Poschke et al.   CLINICAL IMMUNOLOGY

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

(2012) Steffen Walter et al.   NATURE MEDICINE

The secret ally: immunostimulation by anticancer drugs

(2012) Lorenzo Galluzzi et al.   NATURE REVIEWS DRUG DISCOVERY

Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer Models

(2012) Li Shen et al.   PLoS One

Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy

(2012) Li Shen et al.   OncoImmunology

Modulation of antigen-presenting cells by HDAC inhibitors: implications in autoimmunity and cancer

(2011) Karrune V Woan et al.   IMMUNOLOGY AND CELL BIOLOGY

Phase II Study of Belinostat in Patients With Recurrent or Refractory Advanced Thymic Epithelial Tumors

(2011) Giuseppe Giaccone et al.   JOURNAL OF CLINICAL ONCOLOGY

Histone Deacetylase 6 and Heat Shock Protein 90 Control the Functions of Foxp3+ T-Regulatory Cells

(2011) E. F. de Zoeten et al.   MOLECULAR AND CELLULAR BIOLOGY

HDAC inhibitor MS-275 attenuates the inflammatory reaction in rat experimental autoimmune prostatitis

(2011) Zhi-Yuan Zhang et al.   PROSTATE

Mesenchymal Transition and Dissemination of Cancer Cells Is Driven by Myeloid-Derived Suppressor Cells Infiltrating the Primary Tumor

(2011) Benjamin Toh et al.   PLOS BIOLOGY

Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs

(2010) Tatiana Akimova et al.   CLINICAL IMMUNOLOGY

Characterization of Cytokine-Induced Myeloid-Derived Suppressor Cells from Normal Human Peripheral Blood Mononuclear Cells

(2010) M. G. Lechner et al.   JOURNAL OF IMMUNOLOGY

Immune Stimulatory Receptor CD40 Is Required for T-Cell Suppression and T Regulatory Cell Activation Mediated by Myeloid-Derived Suppressor Cells in Cancer

(2009) P.-Y. Pan et al.   CANCER RESEARCH

Induction of Foxp3+ regulatory T cells with histone deacetylase inhibitors

(2009) Julie L. Lucas et al.   CELLULAR IMMUNOLOGY

Epigenetic control of MHC class II expression in tumor-associated macrophages by decoy receptor 3

(2008) Y.-C. Chang et al.   BLOOD

Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity

(2008) K. Movahedi et al.   BLOOD